RxDoctor Payments Data

Ramon Rodriguez, MD

Pulmonary Disease · McAllen, TXNPI 1326093535

Payments from drug & device makers

$13,273in general payments, 2019–2025

Across 315 payments — averaging $42.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$7K
  • GSK$2K
  • AstraZeneca$1K
  • Sanofi$483
  • Insmed, Inc.$469
  • Johnson & Johnson$309
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$6,59850%
  • Food & beverage$6,62750%
  • Education$480%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,273 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$70,097
Medicare patients
183
Services billed
652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter529$377,711
Breztri AerosphereBudesonide/Glycopyr/Formoterol72$48,992
Breo ElliptaFluticasone/Vilanterol73$34,510
Combivent RespimatIpratropium/Albuterol Sulfate55$25,391
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$6,482
Albuterol Sulfate HfaAlbuterol Sulfate164$6,331
SymbicortBudesonide/Formoterol Fumarate22$5,524
Fluticasone-VilanterolFluticasone/Vilanterol14$4,795
BreynaBudesonide/Formoterol Fumarate13$2,797
Wixela InhubFluticasone Propion/Salmeterol16$2,527
Ventolin HfaAlbuterol Sulfate34$2,182
Montelukast Sodium185$1,635
Fluticasone Propionate110$1,298
Cefdinir51$679
Ipratropium Bromide17$396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$1,780$412,221602 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,396$54,51694 claims
Boehringer IngelheimCombivent Respimat$103$25,39155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →